The primary aim of the study was to investigate whether the highly sensitive SiMoA-established biomarker for NFL, GFAP and CXCL13 (representing neurodegeneration and -inflammation) could be detected in the bloodstream of patients with retinal disease. This evidence concerns the gene GFAP and Abnormal retinal morphology.